GLP-3 RTA+ Cagrilintide 15mg Blend Bali
Rp3,700,000.00 ~$224.24
Discover the Atlas Longevity GLP-3 RTA + Cagrilintide Blend 15mg, an experimental research formulation combining two compounds investigated for appetite regulation, body-weight management and metabolic signalling.
Each vial contains:
- GLP-3 RTA : 10mg
- Cagrilintide: 5mg
- Total labelled content: 15mg
- Ratio: 2:1 by mass
- Format: Research peptide vial
- Research Area: Metabolic health and appetite regulation
GLP-3 RTA targets GLP-1, GIP and glucagon receptors, while cagrilintide is a long-acting amylin analogue.
For laboratory research only. Not approved for human consumption or self-administration.
Use code WELCOME20 at checkout. Valid for the first 100 orders only.
Available on backorder
- COA Verified
- Same-Day Dispatch
- Ships from Bali
- SSL Secure
GLP-3 RTA + Cagrilintide Blend 15mg Bali
Reta Cag Dual-Peptide Research Blend
The GLP-3 RTA 10mg + Cagrilintide 5mg Blend combines two investigational peptides in a single vial.
GLP-3 RTA is a triple receptor agonist studied in clinical trials involving obesity and metabolic health.
Cagrilintide is a long-acting amylin analogue investigated for appetite regulation, satiety and weight-management outcomes.
Although the compounds have been investigated individually, this specific combined formulation has not been established as safe or effective in human clinical trials.
What’s Inside the 15mg Blend?
| Ingredient | Quantity | Research Focus |
|---|---|---|
| GLP-3 RTA | 10mg | GLP-1, GIP and glucagon receptor signalling |
| Cagrilintide | 5mg | Amylin receptor signalling and satiety research |
| Total | 15mg | Experimental metabolic peptide blend |
What Is GLP-3 RTA?
GLP-3 RTA is an investigational peptide that activates three hormone receptors:
- GLP-1: Associated with appetite and glucose regulation
- GIP: Involved in glucose-dependent metabolic signalling
- Glucagon: Involved in hepatic metabolism and energy regulation
GLP-3 RTA has been studied in clinical trials for obesity and related metabolic conditions.
What Is Cagrilintide?
Cagrilintide is an investigational long-acting amylin analogue.
Amylin is a hormone involved in appetite regulation, satiety and gastric emptying.
Cagrilintide has been investigated in clinical research involving body-weight management, including studies combining it with semaglutide.
GLP-3 RTA + Cagrilintide Research Areas
The individual ingredients have been studied in relation to:
- Appetite regulation
- Satiety signalling
- Body-weight management
- Glucose metabolism
- Obesity-related metabolic pathways
- Incretin and amylin receptor activity
These research areas do not demonstrate that combining GLP-3 RTA and cagrilintide in one vial produces additional benefits.
GLP-3 RTA + Cagrilintide vs Other Peptides
| Compound | Primary Mechanism |
|---|---|
| GLP-3 RTA | GLP-1 + GIP + Glucagon receptor agonist |
| Cagrilintide | Long-acting amylin analogue |
| Semaglutide | GLP-1 receptor agonist |
| Tirzepatide | GLP-1 + GIP receptor agonist |
| GLP-3 RTA + Cagrilintide | Experimental combination of triple agonist and amylin analogue |
The compounds differ in clinical evidence, regulatory status and safety profile. They are not interchangeable.
Product Specifications
Product: GLP-3 RTA + Cagrilintide Blend
Brand: Atlas Longevity
GLP-3 RTA Content: 10mg
Cagrilintide Content: 5mg
Total Labelled Content: 15mg
Ingredient Ratio: 2:1 by mass
Format: Research peptide vial
Category: Fat Loss & Metabolic Health
Classification: Investigational peptide combination
Intended Use: Laboratory research only
Quality & Batch Documentation
Contact Atlas Longevity to request available batch-specific analytical documentation.
For combination products, testing should assess the identity and quantity of each ingredient wherever validated methods permit.
A Certificate of Analysis does not, by itself, demonstrate sterility, clinical safety or pharmaceutical approval.
Storage
Follow the verified storage instructions supplied for the specific formulation and batch.
Protect from excessive heat, direct sunlight and contamination.
The stability and compatibility of GLP-3 RTA and cagrilintide when combined in one vial should not be assumed without formulation-specific testing.
Safety Information
GLP-3 RTA and cagrilintide are pharmacologically active investigational compounds.
Clinical studies of the individual compounds have reported gastrointestinal adverse effects such as nausea, vomiting and diarrhoea.
The safety, interactions and adverse-effect profile of this specific 15mg blend have not been established.
Atlas Longevity Bali
Atlas Longevity provides information about research peptides and metabolic health compounds.
Contact our team for batch documentation, product specifications and regulatory information.
Any supply must comply with applicable Indonesian regulations.
Frequently Asked Questions
What is GLP-3 RTAv + Cagrilintide Blend?
It is an experimental combination of GLP-3 RTA, a triple receptor agonist, and cagrilintide, a long-acting amylin analogue.
How much peptide is in each vial?
Each vial is labelled as containing 15mg total: 10mg GLP-3 RTA and 5mg cagrilintide.
What is Reta Cag Blend?
Reta Cag is a shortened name sometimes used to describe a GLP-3 RTA and cagrilintide combination.
What does GLP-3 RTA do?
GLP-3 RTA activates GLP-1, GIP and glucagon receptors and has been investigated in clinical trials involving obesity and metabolic conditions.
What does Cagrilintide do?
Cagrilintide is an amylin analogue investigated for its effects on satiety, appetite and body-weight regulation.
Is GLP-3 RTA + Cagrilintide the same as CagriSema?
No. CagriSema refers to a combination of cagrilintide and semaglutide. This blend contains GLP-3 RTA and cagrilintide.
Is GLP-3 RTA + Cagrilintide proven to improve weight loss?
No. The safety and effectiveness of this specific combined formulation have not been established through adequate human clinical trials.
Is the 15mg blend approved for medical use?
No. This combined research formulation is not an established approved medical treatment.
Can the two compounds be stored together?
Compatibility and stability in a single vial require formulation-specific evidence. They should not be assumed based on individual compound data.
Is this blend suitable for injection?
A labelled strength or purity test alone cannot establish sterility, safety or suitability for injection.
Is batch testing documentation available?
Contact Atlas Longevity to request available batch-specific documentation.
Is this blend available in Bali?
Contact Atlas Longevity for product information and regulatory status. Any supply is subject to applicable legal requirements.
Research Disclaimer
For laboratory research purposes only. Not for human consumption.
GLP-3 RTA and cagrilintide are investigational compounds. The combined formulation has not been established as safe or effective for human administration.
This product is not intended to diagnose, treat, cure or prevent any disease.

Peptide Vials
Peptide Pens
Peptide Nasal Sprays
Peptide Protocols
Bundles